RT Journal Article
SR Electronic
T1 Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP 199
OP 202
DO 10.1136/thoraxjnl-2021-217325
VO 77
IS 2
A1 Simon Couillard
A1 Annette Laugerud
A1 Maisha Jabeen
A1 Sanjay Ramakrishnan
A1 James Melhorn
A1 Timothy Hinks
A1 Ian Pavord
YR 2022
UL http://thorax.bmj.com/content/77/2/199.abstract
AB Reduction of the risk of asthma attacks is a major goal of current asthma management. We propose to derive a risk scale predicting asthma attacks based on the blood eosinophil count and exhaled nitric oxide (FeNO). Biomarker-stratified trial-level attack rates were extracted and pooled from the control arms of the Novel START, CAPTAIN, QUEST, Benralizumab Phase 2b, PATHWAY, STRATOS 1–2 and DREAM trials (n=3051). These were used to derive rate ratios and the predicted asthma attack rate for different patient groups. The resultant prototype risk scale shows potential to predict asthma attacks, which may be prevented by anti-inflammatory treatment.